Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.
The efficacy and safety of oral verapamil, 240 mg, with or without digoxin were studied in 52 patients with chronic atrial fibrillation at rest, and during mild and maximal exercise. Twenty-four patients were studied during the following therapeutic modalities: no therapy; digoxin, 0.25 mg and 0.5 mg daily; digoxin, 0.25 mg and verapamil; and verapamil alone. Heart rate at rest and during all levels of exercise was decreased significantly (p less than 0.005), either by combining digoxin with verapamil or by verapamil therapy alone. In contrast, the excessive heart rate response to exercise was not prevented by digoxin even with good serum concentrations. The improved control of heart rate with verapamil was associated with a significantly improved exercise capacity. Verapamil is an important and safe modality of treatment, with or without digoxin, in the long-term control of heart rate in chronic atrial fibrillation. It is superior to digoxin in controlling the ventricular rate and in improving exercise capacity.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005080:Exercise Test; D005260:Female; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014700:Verapamil / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*
D004077:Digoxin; D014700:Verapamil